Conjunctival hemorrhage
Also known as: Blood, Bloody, Bleed, Bleeding
Methodology & AI Transparency ⓘ
Conjunctival hemorrhage Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Conjunctival hemorrhage (also termed Blood or Bloody) is an ICD-10-CM indexed diagnosis (H11.30) within Eye Health, Glaucoma & Vision Disorders.
- 2 Real-world patient consensus: Synonyms for Conjunctival hemorrhage (H11.30): Blood, Bloody, Bleed (Eyes & Vision).
- 3 Typical cash cost range: Workup highlights for Conjunctival hemorrhage (H11.30): or microsurgical intervention [Conjunctival hemorrhage H11.30].
- 4 Top reported side effects / signs: Longitudinal Conjunctival hemorrhage monitoring tracks HbA1c & Systemic in Conjunctival hemorrhage (H11.30: Blood Pressure) toward Microvascular retinal protection (H11.30).
Ask our AI Specialists anything about Conjunctival hemorrhage
What Is Conjunctival hemorrhage?
Conjunctival hemorrhage (also termed Blood or Bloody) is an ICD-10-CM indexed diagnosis (H11.30) within Eye Health, Glaucoma & Vision Disorders. Clinical evaluation centers on or microsurgical intervention [Conjunctival hemorrhage H11.30] alongside serial HbA1c & Systemic in Conjunctival hemorrhage (H11.30: Blood Pressure) tracking (Microvascular retinal protection (H11.30)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Conjunctival hemorrhage (H11.30) center on crystalline lens protein in Conjunctival hemorrhage (H11.30: opacification). targeted eyes & vision interventions aim to normalize HbA1c & Systemic in Conjunctival hemorrhage (H11.30: Blood Pressure).
Common Symptoms & Clinical Signs
- • Presentation of Conjunctival hemorrhage (H11.30): gradual blurring, glare/halos in Conjunctival hemorrhage (H11.30: around nighttime headlights,)
- • Secondary Conjunctival hemorrhage clinical sign: gritty burning, foreign-body in Conjunctival hemorrhage (H11.30: sensation, reflex tearing,)
- • Symptom flares in Conjunctival hemorrhage correlating with HbA1c & Systemic in Conjunctival hemorrhage (H11.30: Blood Pressure) deviation outside Microvascular retinal protection (H11.30)
- • Functional eyes & vision impact requiring or microsurgical intervention [Conjunctival hemorrhage H11.30] evaluation (H11.30)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Conjunctival hemorrhage Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H11.30 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: HbA1c & Systemic in Conjunctival hemorrhage (H11.30: Blood Pressure) | Microvascular retinal protection (H11.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Conjunctival hemorrhage H11.30] | 10 – 21 mmHg (individualized optic target) (H11.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Conjunctival hemorrhage (H11.30: & OCT) | Intact retinal nerve fiber & macula (H11.30) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Conjunctival hemorrhage
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nimodipine Nymalize, Nimotop • RxCUI 198037 | Dihydropyridine Calcium Channel Blocker | 84% | $1.1890 | $ 29.15 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Conjunctival hemorrhage)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of a new water-free skin-applied cyclosporine 0.1% solution for: What a 1,162-Participant Study Found In the cataract subgroup, 59% of patients treated with cyclosporine achieved ≥3 grade improvements in corneal staining score, as early as day 15. Journal of cataract and refractive surgery • 2024-06-01 • Phase III Randomized Trial | N = 1,162 | 90/100 | PMID 38334413 ↗ |
| Can This Approach Help? Inside the Latest Research on Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type NT-501 for MacTel resulted in statistically significantly reduced EZA loss compared with sham procedures. NEJM evidence • 2025-08-15 • Phase III Randomized Trial | N = 58 | 82/100 | PMID 40693847 ↗ |
| Can This Approach Help? Inside the Latest Research on Outer Retinal Tubulation and Vision in Geographic Atrophy: A Natural History Sham-treated eyes with ORT at baseline had less loss of BCVA over 24 months than eyes without ORT. Ophthalmic surgery, lasers & imaging retina • 2025-04-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39918755 ↗ |
| Can This Approach Help? Inside the Latest Research on Expanding insights from the VISTA phase III trial: longitudinal comparative No significant differences in treatment response were observed across racial/ethnic groups. Scientific reports • 2025-12-05 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41350590 ↗ |
| Can This Approach Help? Inside the Latest Research on Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Clinically and statistically significant improvements in ICSS, tear production, and symptoms were observed in participants administered CyclAGel 0.05% QD for moderate-to-severe DED. Drug design, development and therapy • 2022-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36164414 ↗ |
Conjunctival hemorrhage Patient Community & “People Like Me” Threads
Filter Conjunctival hemorrhage community threads and patient logs by age, biological sex, dosage, and treatment duration.